Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2022;33(4):471-7
JAK Inhibition in Patients with Rheumatoid Arthritis: Haemodynamic Effects and Impact on Micro- and Macrovascular Function. Study Design and Rationale
Authors Information

1Second Medical Department, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

2Fourth Department of Internal Medicine, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

References
  1. Almutairi K, Nossent J, Preen D, Keen H, Inderjeeth C. The global prevalence of rheumatoid arthritis: a meta-analysis based on a  systematic review. Rheumatol Int 2021;41:863-77.
  2. Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis 2016;8:86-101.
  3. Anyfanti P, Triantafyllou A, Gkaliagkousi E, Triantafyllou G, Koletsos N, Chatzimichailidou S, et al. Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors. Clin Rheumatol 2017;36:1229-36.
  4. Anyfanti P, Triantafyllou A, Gkaliagkousi E, Koletsos N, Athanasopoulos G, Zabulis X, et al. Retinal vessel morphology in rheumatoid arthritis: association with systemic inflammation, subclinical atherosclerosis and cardiovascular risk. Microcirculation 2017;24.
  5. Anyfanti P, Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Dolgyras P, Galanopoulou V, et al. Association of galectin-3 with markers of myocardial function, atherosclerosis, and vascular fibrosis in patients with rheumatoid arthritis. Clin Cardiol 2018;42:62-8.
  6. Anyfanti P, Gavriilaki E, Douma S, Gkaliagkousi E. Endothelial Dysfunction in Patients with Rheumatoid Arthritis: the Role of Hypertension. Curr Hypertens Rep 2020;22:56.
  7. Xu S-Z, Wang P, Guan S-Y, Li H-M, Leng R-X, Pan H-F, et al. Decreased flow-mediated dilatation in patients with rheumatoid arthritis: a  meta-analysis. Postgrad Med J England; 2017;93:260-5.
  8. Anyfanti P, Gavriilaki E, Nikolaidou B, Yiannaki E, Lazaridis A, Papadopoulos N, et al. Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. J Thromb Thrombolysis 2022;53:10-16.
  9. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2018;77:48-54.
  10. Panoulas VF, Metsios GS, Pace AV, John H, Treharne GJ, Banks MJ, et al. Hypertension in rheumatoid arthritis. Rheumatology 2008;47:1286-98.
  11. Anyfanti P, Gkaliagkousi E, Triantafyllou A, Koletsos N, Gavriilaki E, Galanopoulou V, et al. Hypertension in rheumatic diseases: prevalence, awareness, treatment, and control rates according to current hypertension guidelines. J Hum Hypertens 2021;35:419-427.
  12. Anyfanti P, Dara A, Angeloudi E, Bekiari E, Dimitroulas T, Kitas GD. Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory  Diseases. J Inflamm Res 2021;14:6893-906.
  13. Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, D Kitas G. Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk  Reduction. J Inflamm Res 2021;14:1915-31.
  14. Harrington R, Al Nokhatha SA, Conway R. Jak inhibitors in rheumatoid arthritis: An evidence-based review on the emerging clinical data. J Inflamm Res 2020;13:519-31.
  15. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:S685-99.
  16. Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: Systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 2019;78:1048-54.
  17. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 2022;386:316-26.
  18. Singh JA. Risks and Benefits of Janus Kinase Inhibitors in Rheumatoid Arthritis - Past,  Present, and Future. N Engl J Med 2022;386:387-9.
  19. Kotyla PJ, Islam MA, Engelmann M. Clinical aspects of Janus Kinase (JAK) inhibitors in the cardiovascular system in patients with rheumatoid arthritis. Int J Mol Sci 2020;21:1-17.
  20. Mancia G, Verdecchia P. Clinical Value of Ambulatory Blood Pressure: Evidence and Limits. Circ Res 2015;116:1034-45.
  21. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens 2018;36:1953-2041.
  22. Gkaliagkousi E, Anyfanti P, Chatzimichailidou S, Triantafyllou A, Lazaridis A, Aslanidis S, et al. Association of nocturnal blood pressure patterns with inflammation and central and peripheral estimates of vascular health in rheumatoid arthritis. J Hum Hypertens 2018;32:259-67.
  23. Vlachopoulos C, O‘Rourke M. Genesis of the normal and abnormal arterial pulse. Curr Probl Cardiol 2000;25:303-67.
  24. Gkaliagkousi E, Douma S. The pathogenesis of arterial stiffness and its prognostic value in essential hypertension and cardiovascular diseases. Hippokratia 2009;13:70-5.
  25. Vlachopoulos C, Aznaouridis K SC. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-27.
  26. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: Methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
  27. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-5.
  28. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Mbbc H, et al. Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction An Individual Participant Meta-Analysis of Prospective Observational Data From 17 , 635 Subjects. J Am Coll Cardiol 2014;63:636-43.
  29. Anyfanti P, Bekiari E, Angeloudi E, Pagkopoulou E, Kitas G, Dimitroulas T. Arterial stiffness in rheumatoid arthritis: Current knowledge and future perspectivess. Indian J Rheumatol 2022;17:157-65.
  30. Soulaidopoulos S, Triantafyllidou E, Garyfallos A, Kitas GD, Dimitroulas T. The role of nailfold capillaroscopy in the assessment of internal organ involvement in systemic sclerosis: A critical review. Autoimmun Rev 2017;16:787-95.
  31. Minopoulou I, Theodorakopoulou M, Boutou A, Arvanitaki A, Pitsiou G, Doumas M, et al. Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary  Arterial Hypertension: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:15-28.
  32. Soulaidopoulos S, Pagkopoulou E, Katsiki N, Triantafyllidou E, Karagiannis A, Garyfallos A, et al. Arterial stiffness correlates with progressive nailfold capillary microscopic  changes in systemic sclerosis: results from a cross-sectional study. Arthritis Res Ther 2019;21:253.
  33. Pagkopoulou E, Soulaidopoulos S, Triantafyllidou E, Arvanitaki A, Katsiki N, Loutradis C, et al. Peripheral microcirculatory abnormalities are associated with cardiovascular risk  in systemic sclerosis: a nailfold video capillaroscopy study. Clin Rheumatol Germany; 2021;40:4957-68.
  34. Pagkopoulou E, Soulaidopoulos S, Triantafyllidou E, Malliari A, Kitas GD, Garyfallos A, et al. Association Between Uric Acid and Worsening Peripheral Microangiopathy in  Systemic Sclerosis. Front Med 2021;8:806925.
  35. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 2006;45:43-6.
  36. IJzerman RG, De Jongh RT, Beijk MAM, Van Weissenbruch MM, Delemarre-van De Waal HA, Serné EH, et al. Individuals at increased coronary heart disease risk are characterized by an impaired microvascular function in skin. Eur J Clin Invest 2003;33:536-42.
  37. Triantafyllou A, Anyfanti P, Zabulis X, Gavriilaki E, Karamaounas P, Gkaliagkousi E, et al. Accumulation of microvascular target organ damage in newly diagnosed hypertensive patients. J Am Soc Hypertens 2014;8:542-9.
  38. Maldonado G, Guerrero R, Paredes C, Ríos C. Nailfold capillaroscopy in diabetes mellitus. Microvasc Res 2017;112:41-6.
  39. Schoina M, Loutradis C, Memmos E, Dimitroulas T, Pagkopoulou E, Doumas M, et al. Microcirculatory function deteriorates with advancing stages of chronic kidney  disease independently of arterial stiffness and atherosclerosis. Hypertens Res 2021;44:179-87.
  40. Triantafyllou A, Anyfanti P, Pyrpasopoulou A, Triantafyllou G, Aslanidis S, Douma S. Capillary Rarefaction as an Index for the Microvascular Assessment of Hypertensive Patients. Curr Hypertens Rep 2015;17:33.
  41. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Pagkopoulou E, Boutou A, Garyfallos A, et al. Nailfold videocapillaroscopic changes in patients with pulmonary arterial  hypertension associated with connective tissue diseases. Rheumatol Int Germany; 2021;41:1289-98.
  42. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Feloukidis C, Boutou A, Garyfallos A, et al. Peripheral microangiopathy in Eisenmenger syndrome: A nailfold video  capillaroscopy study. Int J Cardiol 2021;336:54-9.
  43. Arvanitaki A, Giannakoulas G, Triantafyllidou E, Feloukidis C, Boutou AK, Garyfallos A, et al. Peripheral microangiopathy in precapillary pulmonary hypertension: a nailfold  video capillaroscopy prospective study. Respir Res 2021;22:27.
  44. Anyfanti P, Angeloudi E, Dara A, Arvanitaki A, Bekiari E, Kitas GD, et al. Nailfold Videocapillaroscopy for the Evaluation of Peripheral Microangiopathy in  Rheumatoid Arthritis. Life (Basel, Switzerland) 2022;12.
  45. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS H LA, et al. the American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis. Arthritis Rheum 1988;31:315-24.
  46. Criteria Committee, New York Heart Association I. Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for diagnosis. 6th Edition. Little, Brown and Co.; 1964. p. 114.
  47. Wei W, Tölle M, Zidek W, van der Giet M. Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit 2010;15:225-8.
  48. Franssen PML, Imholz BPM. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit 2010;15:229-31.
  49. Crowson CS, Gabriel SE, Semb AG, van Riel PLCM, Karpouzas G, Dessein PH, et al. Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology  2017;56:1102-10.
  50. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: The Framingham heart study. Circulation 2008;117:743-53.
  51. Anyfanti P, Gkaliagkousi E, Triantafyllou A, Zabulis X, Dolgyras P, Galanopoulou V, et al. Dermal capillary rarefaction as a marker of microvascular damage in patients with rheumatoid arthritis: Association with inflammation and disorders of the macrocirculation. Microcirculation 2018;25:e12451.